Home - Arizona Pharmacy Association

AzPA Immunization Certificate Program

SEPTEMBER 29-30TH | GLENDALE, AZ

This program is an interactive educational program that provides pharmacists and student pharmacists with the skills necessary to become primary sources for vaccine advocacy, education, and administration.

APhA Delivering Medication Therapy Management

OCTOBER 13th | TUCSON, AZ

This program presents a systematic approach for developing, implementing, delivering, and sustaining MTM services. The purpose of this certificate training program is to prepare pharmacists to improve medication use through the delivery of MTM services in a variety of practice settings.

AzPA Anticoagulation Certificate Program

NOVEMBER 9, 2018 | FLAGSTAFF, AZ

Gain an understanding of the clotting cascade and mechanisms of action of anticoagulant therapies, a detailed focus on factors which influence therapy and knowledge of current guidelines.

AzPA Psychiatric Certificate Program

DECEMBER 15th | TUCSON, AZ

A practice-based activity designed for pharmacists in all practice settings. The intent of this training program is to provide additional training in the area of psychiatric pharmacy to enhance pharmacists’ clinical knowledge that can be applied directly to the patients they serve.

AzPA Pain Management Certificate Program

DECEMBER 8th | VIRTUAL WEBINAR

Innovative and comprehensive learning activity developed to assist pharmacists to maintain and enhance their professional competencies in pain management.

Educate

Businessman hand holding the futuristic network connection techn

Learn with us

Advocate

Discover your voice

Connect

Get involved! Serve on a team

Connect with us.

Pharmacy Flash

AzPA Pharmacy Flash

FDA approves Teva's Cassipa for treatment of opioid dependence
The Food and Drug Administration has given the nod to Teva’s Cassipa (buprenorphine and naloxone) sublingual film, or applied under the tongue, for the maintenance treatment of opioid dependence. This action provides a new dosage strength (16 ml/4 ml) of buprenorphine and naloxone sublingual film, which also is approved in both brand name and generic […]
Study: Use of generic combination drugs could have drastically reduced Medicare spending
Spending for the 10 most expensive brand name combination drugs could have been reduced by an estimated $2.7 billion between 2011 and 2016 if lower-cost generics had been prescribed, according to researchers from Brigham and Women’s Hospital and Harvard Medical School.
Study shows it takes longer to develop and approve CNS drugs than non-CNS products
Developing drugs to treat central nervous system (CNS) disorders on average required 20 percent more time than other drugs that won marketing approval in the U.S. from 2000 through 2017, and took 38 percent longer to win that approval, according to a newly completed analysis by the Tufts Center for the Study of Drug Development. […]